Brief: CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data

CEL-SCI

11/07/2023 14:30

July 11 (Reuters) - CEL-SCI Corp  CVM.A :
    * CEL-SCI REPORTS PHASE 3 TUMOR PD-L1 BIOMARKER DATA
DEMONSTRATE
MULTIKINE’S INCREASED EFFICACY AND POINTS TO POTENTIAL FOR
COMBINATION WITH CHECKPOINT INHIBITORS FOR HEAD & NECK CANCER
    * CEL-SCI - MULTIKINE SIGNIFICANTLY INCREASES OVERALL
SURVIVAL IN
PATIENTS WITH LOW LEVELS OF TUMOR CELL PD-L1 EXPRESSION VERSUS
APPROVED CHECKPOINT INHIBITORS

Source text for Eikon:  ID:nBwFSSGYa 
Further company coverage:  CVM.A 

 ((Reuters.Briefs@thomsonreuters.com;))